Format

Send to

Choose Destination
Climacteric. 2012 Oct;15(5):490-5. doi: 10.3109/13697137.2011.631063. Epub 2011 Dec 23.

One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome.

Author information

1
Department of Obstetrics and Gynecological Sciences, University of Messina, Messina, Italy.

Abstract

OBJECTIVE:

To evaluate the 12-month effect of myo-inositol treatment on some biochemical parameters of women affected by metabolic syndrome.

METHODS:

Eighty outpatient postmenopausal women, affected by metabolic syndrome, were enrolled in a 12-month study. All women were treated with a low-energy diet, and then they were randomly assigned to myo-inositol 2 g b.i.d. (n = 40) or placebo (n = 40). All the women were evaluated for serum glucose, insulin, HOMA-IR (Homeostasis Model Assessment-Insulin Resistance), triglycerides, total and high density lipoprotein cholesterol, body mass index (BMI), waist circumference and blood pressure at baseline and after 12 months of treatment.

RESULTS:

With the exception of BMI and waist circumference, after 12 months of treatment, all the parameters studied showed a significant improvement in the myo-inositol group compared to the control group. At the end of the study, in the myo-inositol group, the number of women without metabolic syndrome was eight (20%) whereas, in the control group, only one woman no longer had the metabolic syndrome after 12 months of diet.

CONCLUSIONS:

Myo-inositol might be considered one of the insulin-sensitizing substances in the treatment of metabolic syndrome.

PMID:
22192068
DOI:
10.3109/13697137.2011.631063
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center